[1] VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD executive summary[J]. Am J Respir Crit Care Med, 2017, 195(5):557-582. [2] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131):1706-1717. [3] 沈奕播, 聂洪玉, 李琦. 慢性阻塞性肺疾病合并肺动脉高压患者的临床特征与危险因素分析[J]. 中华老年多器官疾病杂志, 2018, 17(5):371-375. [4] RUOPP N F, COCKRILL B A. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327(14):1379-1391. [5] MANDAL J, ROTH M, COSTA L, et al. Vasoactive intestinal peptide for diagnosing exacerbation in chronic obstructive pulmonary disease[J]. Respiration, 2015, 90(5):357-368. [6] SAID S I. Vasoactive intestinal peptide in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2012, 185(7):786. [7] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中国医学前沿杂志(电子版), 2014, 6(2):67-80. [8] FISHER M R, CRINER G J, FISHMAN A P, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema[J]. Eur Respir J, 2007, 30(5):914-921. [9] SUBIAS P E. Comments on the 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol, 2016, 69(2):102-108. [10] HASSOUN P M. Pulmonary arterial hypertension[J]. N Engl J Med, 2021, 385(25): 2361-2376. [11] 符沙沙, 陈宗存, 王志峰, 等. 老年慢性阻塞性肺疾病相关肺动脉高压、高凝状态与血清脂联素、8-异前列腺素F2α的关系[J]. 实用老年医学, 2022, 36(2):180-183. [12] 马莉莉, 蒋麟, 付丽, 等. 慢性阻塞性肺病患者的血管内皮功能损伤程度与其严重程度的相关性[J]. 中华老年医学杂志, 2018, 37(5):514-517. [13] THEODORAKOPOULOU M P, BAKALOUDI D R, DIPLA K, et al. Vascular endothelial damage in COPD: current functional assessment methods and future perspectives[J]. Expert Rev Respir Med, 2021, 15(9):1121-1133. [14] ZAIA C, UCHOA E T, SANTOS A, et al. Vasoactive intestinal peptide promotes hypophagia and metabolic changes: Role of paraventricular hypothalamic nucleus and nitric oxide[J]. Brain Res Bull, 2022, 189:102-110. [15] CAI J, CHEN Q, MEHRABI NASAB E, et al.Immunomodulatory effect of N-acetyl-seryl-aspartyl-proline and vasoactive intestinal peptide on chronic obstructive pulmonary disease pathophysiology[J]. Fundam Clin Pharmacol, 2022, 36(6):1005-1010. [16] DUAN J X, GUAN X X, YANG H H, et al. Vasoactive intestinal peptide attenuates bleomycin-induced murine pulmonary fibrosis by inhibiting epithelial-mesenchymal transition: restoring autophagy in alveolar epithelial cells[J]. Int Immunopharmacol, 2021, 101(Pt B):108211. [17] 惠毅, 闫曙光, 李京涛, 等. 血管活性肠肽调控肺泡巨噬细胞M1/M2极化治疗急性肺损伤的研究进展[J]. 中国免疫学杂志, 2022, 38(8):1008-1011. [18] SUN G Y, YANG H H, GUAN X X, et al. Vasoactive intestinal peptide overexpression mediated by lentivirus attenuates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation[J]. Mol Immunol, 2018, 97: 8-15. [19] ZHOU Y, ZHANG C Y, DUAN J X, et al. Vasoactive intestinal peptide suppresses the NLRP3 inflammasome activation in lipopolysaccharide-induced acute lung injury mice and macrophages[J]. Biomed Pharmacother, 2020, 121:109596. [20] 王旭艳, 张新悦, 闫曙光, 等. 血管活性肠肽对肺泡巨噬细胞活化和p38MAPK信号通路影响的实验研究[J]. 免疫学杂志, 2022, 38(4):316-323. [21] 柯莉芹, 王凤美, 罗运春. 血管活性肠肽对哮喘小鼠气道炎症及Th17/Treg平衡的影响[J]. 中国当代儿科杂志,2017,19(6):699-704. [22] 惠毅, 魏海梁, 闫曙光, 等. 血管活性肠肽对肺泡巨噬细胞M1/M2型极化及相关细胞因子的影响[J]. 中国现代应用药学,2021,38(17):2053-2059. [23] WANG J, SHANG Y X, CAI X X, et al. Vasoactive intestinal peptide inhibits airway smooth muscle cell proliferation in a mouse model of asthma via the ERK1/2 signaling pathway[J]. Exp Cell Res,2018, 364(2):168-174. [24] 王娟, 尚云晓. 血管活性肠肽对哮喘气道重塑小鼠肺组织PCNA表达的影响[J]. 国际儿科学杂志, 2018,45(7):543-545,550. |